FY4/23 1Q
Supplementary Materials

September 2, 2022

１．Consolidated Results■Year-on-Year(¥ million)

FY4/22 1Q
results

FY4/23 1Q
results

YoYchange

YoYchange(%)

Net sales

75,011

81,470+6,459+8.6

Gross profit

11,06011,643+583+5.3

8,448

8,890+442+5.2

2,611

2,753+142+5.4

2,864

3,089+225+7.9

Profit attributableto owners of parent

1,309

1,704+395+30.2

Earnings pershare(¥)

37.10

48.53+11.43+30.8% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

14.7

14.3

11.3

10.9

3.5

3.4

3.8

3.8

1.7

% of net sales

2.1

Figures in the table are rounded down

■Vs Plan(¥ million)

FY4/23 1Q
plan

FY4/23 1Q
results

Vs planchangeVs planchange(%)

Net sales

81,887

81,470(417)(0.5)

Gross profit

12,471

11,643(828)

(6.6)

9,413

8,890(523)

(5.6)

3,058

2,753(305)(10.0)

3,180

3,089(91)(2.9)

Profit attributableto owners of parent

1,450

1,704+254+17.5

Earnings pershare(¥)

41.1948.53+7.34+17.8% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

15.2

14.3

11.5

10.9

3.7

3.4

3.9

3.8

2.1

1.8

% of net sales

Figures in the table are rounded down

-1-２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year(¥ million)

FY4/22 1Q
results

FY4/23 1Q
results

YoYchange

YoYchange(%)

Net sales

66,82872,482+5,654+8.5

Gross profit

8,138

8,327+189+2.3

SG&A expenses

3,396

3,840+444+13.1

Operating profit

4,742

4,486(256)(5.4)

4,731(148)(3.0)% of net sales% of net sales% of net sales

Segment income% of net sales

12.2

11.5

5.1

5.3

7.1

6.2

4,879
7.3

6.5

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income■Vs Plan(¥ million)

FY4/23 1Q
plan

FY4/23 1Q
results

Vs planchangeVs planchange(%)

Net sales

72,81072,482(328)(0.5)

Gross profit

9,150

8,327(823)(9.0)

SG&A expenses

3,870

3,840(30)(0.8)

Operating profit

5,280

4,486(794)(15.0)

5,390

4,731(659)(12.2)% of net sales% of net sales% of net sales

Segment income% of net sales

12.6

11.5

5.3

5.3

7.3

6.2

7.4

6.5

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year(¥ million)

FY4/22 1Q
results

FY4/23 1Q
results

YoYchange

YoYchange(%)

Net sales

5,063

6,086+1,023+20.2

Gross profit

1,701

2,245+544+32.0% of net sales

33.6

36.9

SG&A expenses

2,213

2,098(115)(5.2)

Operating profit(511)

146+657-

Segment income(503)

164+667-% of net sales% of net sales% of net sales

43.7

34.5-

2.4-

2.7

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income■Vs Plan(¥ million)

FY4/23 1Qplan

FY4/23 1Q
results

Vs planchangeVs planchange(%)

Net sales

6,130

6,086(44)(0.7)

Gross profit

2,2562,245(11)

(0.5)

2,276

2,098(178)(7.8)

Operating profit(20)

146+166-

Segment income(20)

164+184-% of net sales

SG&A expenses% of net sales% of net sales% of net sales

36.8

36.9

34.5

37.1

-

2.4-

2.7

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the quarterly consolidated statement of income-3-

4. Sales Verification■Dispensing Pharmacy Business (YoY）■Dispensing Pharmacy Business（Vs Plan）

Net sales

Net sales（%）

Average
Prescription
prescriptionvolume（%）
price

Average
Prescription
prescription
volumeprice

Same store (1,044)+0.3+0.2+0.1

Same store (1,044)(0.8)

0.0(0.8)

Store openings in theprevious year (49)+760.3+703.9+7.2

Store openings in theprevious year (49)

(1.9)

(3.9)

+2.1+8.2

+7.8

+0.4

Total (1,210)

(0.7)

(0.4)

(0.3)

Total (1,210)■Cosmetic and Drug Store Business（YoY）■Cosmetic and Drug Store Business (Vs Plan）

Net sales

Net sales（%）
Same store (65)Store openings in theprevious year (11)Total (79)

Average
Number ofspending per
customers
customer（%）

Average
Number ofspending per
customers
customer+16.8(5.5)

Same store (65)+0.7+3.8(3.0)+8,490.3 +8,039.1+5.5Store openings in theprevious year (11)(11.6)

(4.3)

(7.6)

(6.0)

Total (79)(0.7)

+2.4(3.1)

+10.4

+20.2

+27.9

Changed accounting policies for revenue recognition from FY4/22-4-

5. Consolidated Balance Sheet■Assets(¥ million)
Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,netLand
Total property,plant andequipment
Goodwill
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets
Total deferred assets
Total assets

End-FY4/22 1Q

End-FY4/22

End-FY4/23 1Q

Change53,576
12,33815,18094,82916,3459,976

59,729
10,11014,790100,765
17,512
8,581

46,863
12,697
19,504
96,163
19,505
10,637(12,866)+2,587+4,714(4,602)+1,993+2,056

30,11730,63635,755+5,11939,07942,788
2,638
4,633
21,31336,352
41,2192,503
5,319
22,78549,34454,4792,649
5,957
23,234+12,992+13,260+146+638+449

35,817

39,84041,996+2,156

108,722
203,552

111,696
212,461

132,231228,394+20,535+15,933

Figures in the table are rounded down

Change:End-FY4/23 1Q compared with end-FY4/22
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥3,210million■Liabilities and Net Assets(¥ million)

End-FY4/22 1Q

End-FY4/22

Total liabilities and net assets

49,094
3,354
76,816
7,507
12,962
89,77821,89420,50072,878113,870
113,773
203,552

Figures in the table are rounded down

Change:End-FY4/23 1Q compared with end-FY4/22

Accounts payable
Short-term debt
Total current liabilities
Long-term debt
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

50,7562,643
81,805
5,815
11,64593,45021,89420,500
78,661
119,038
119,010
212,461End-FY4/23 1Q-5-

59,462
4,167
91,402
11,21818,217
109,620
21,89420,50078,433
118,811
118,773
228,394

Change+8,706+1,524+9,597+5,403+6,572+16,170
(228)
(227)
(237)
+15,933

6. FY4/23 Plan (Consolidated)(¥ million)
Net sales

297,305

316,247

363,000+46,753+14.8

Gross profit

46,15549,97158,720+8,749+17.5

35,222

34,832

38,720+3,888+11.2

10,932

15,13920,000+4,861+32.1

12,64916,041

20,500+4,459+27.8

Profit attributableto owners of parent

6,697

7,092

11,000+3,908+55.1

Earnings pershare(¥)

189.04201.47313.15+111.68+55.4

Annual dividend (¥)

55.00

55.00

60.00

+5.00

+9.1

% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales% of net sales

15.5

11.8

3.7

4.3

2.3

FY4/22
results

YoYchange

FY4/21
results

15.8

11.0

4.8

5.1

2.2

Figures in the table are rounded down
Change:FY4/23 plan compared with FY4/22 results-6-FY4/23
plan16.210.75.55.63.0

YoYchange (%)

7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22

FY4/231QOrganic

4032272523

1415258M&A119110182

11134

61424109Total

754881

1,066

1,029

1,132

1,088

1,065

1,0991,210■Number of Store Openings in Cosmetic and Drug Store Business
FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22

FY4/231QOrganic

359471511122Total

56

5252

48

54

63

69

7879Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/This document may not be reproduced or distributed to any third party withoutprior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-